Skip to main content

Industry News

  • Biocon Ltd announced that it has signed a License and Supply Agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for three Generic Formulation products in Greater China. 

    Biocon Ltd announced that it has signed a License and Supply Agreement with a subsidiary of China Medical System Holdings Ltd. (CMS) for three Generic Formulation products in Greater China.

  • EMA has recommended new measures to prevent serious and potentially fatal errors with the dosing of methotrexate for treating inflammatory diseases such as rheumatoid arthritis, psoriasis and Crohn’s disease. The recommendations result from a review of reports that patients are using methotrexate incorrectly despite previous measures to prevent errors.

  • Global Market Insights, Inc., announces a research report on ‘Vaccines Market Trends and Forecast 2019-2025’. The report covers an extensive summary of the age group, technology, disease, regional, and competitive landscapes. Global Vaccines industry revenue is set to exceed $72.5 billion by 2025.

    Global vaccines market size has expanded rapidly owing to increased prevalence of chronic disorders and a rising population base. Improved healthcare systems and better awareness throughout emerging economies has strengthened the demand for critical therapies, while higher disposable incomes and favorable health insurance policies have enabled access to advanced treatment options.

  • Pharmaceutical Companies which introduced 22 drugs without prior approval of the National Pharmaceutical Pricing Authority (NPPA) have been issued notices by Government. The NPPA regularly takes action against such companies as per provisions of the Drugs (Prices Control) Order, 2013 (DPCO) which has been issued under the Essential Commodities Act, 1955.

  • InvaGen Pharmaceuticals, Inc. a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited announced the receipt of final approval for its Abbreviated New Drug Application (ANDA) for Pregabalin Capsules, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg and 300mg from the United States Food and Drug Administration (US FDA).

    (adsbygoogle = window.adsbygoogle || []).push({});
  • According to the report by Transparency Market Research, the global active pharmaceutical ingredients market is projected to worth approximately US$257.5 bn by the end of 2026. It is noticeable that the market valued nearly US$160.0 bn during 2017. This means that the market is expected to witness the growth with staggering 5.4% CAGR from 2018 to 2026.

Subscribe to Industry News